We read with interest the study by Chen and associates that showed that simvastatin reduces neointimal proliferation in mice after vascular injury in a cholesterol-independent manner. 1 However, we already documented this finding in vitro and in vivo in a previous article. 2 In fact, it has been documented that simvastatin inhibits in vitro smooth muscle cell proliferation independent of cholesterol. 2 In addition, in vivo experiments have shown that statins potently affect neointimal proliferation in a dose-dependent manner in a reliable model of balloon injury in the rat. 2 This effect was abolished by local administration of mevalonate. 2 We are delighted that the study of Chen et al confirms, 1 in genetically modified mice, our findings. 2 With regard to the potential mechanism of statin on neointimal proliferation, we previously discussed a key role of ras pathway in neointimal proliferation after balloon injury. 3 Recently, we also showed that statins powerfully inhibit ras farnesilation and activation. 4 Therefore, statin-induced Ras-MAPKKs pathway inhibition may play a critical role in the effect of simvastatin on neointimal formation after vascular injury.
